(Photo: Phillip / flickr)
Mar 05, 2013
Pharmaceutical giant Bayer has been dealt a blow with a precedent-setting ruling that allows the production of a low-cost version of its patented cancer drug Nexavar in India, vastly expanding access to the drug and challenging the global pharmaceutical monopolies that put potentially life-saving drugs out of reach for many.
On Monday, the Intellectual Property Appellate Board (IPAB) upheld a compulsory license given by India last year to Hyderabad-based Natco Pharma for its generic version of Nexavar, used in the treatment of kidney and liver cancer, dismissing a plea from Bayer to overturn that license.
As Reuters explains,
Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licenses on certain drugs that are deemed unaffordable to a large section of their populations.
Natco Pharma's version costs roughly 97% less than Bayer's Nexavar.
The ruling, the first in which the IPAB said the use of a compulsory license was legal, also stated that Natco would have to pay Bayer 7% in royalties for the drug.
In an interview with The Economic Times, Finance Director of Natco Pharma Bhaskar Narayana stated the importance of the landmark ruling.
"This only means that the IPAB has reaffirmed the crucial concept of making life-saving medicines available and affordable to the suffering masses. Therefore, it is big news not only for Natco Pharma, but also for the millions of cancer patients who cannot afford high value drugs," stated Narayana.
Health groups cheered the decision as well.
"The decision means that the way has been paved for compulsory licenses to be issued on other drugs, now patented in India and priced out of affordable reach, to be produced by generic companies and sold at a fraction of the price," BBC News quoted Leena Menghaney of the medical charity Medecins Sans Frontieres (MSF) as saying.
While representing a victory for people, the Connecticut Law Tribune points out how the ruling may leave big pharmaceutical firms shaking:
This is exactly what multinational pharmaceutical companies fear. While this is the first case of a compulsory license in India, drug makers are worried about their patents in India for other reasons. The country has already revoked some patents granted to Pfizer, Roche Holding AG, and Merck & Co., for example. And it rejected Swiss drug maker Novartis's patent application for the leukemia drug Glivec. Novartis appealed that ruling, and has been awaiting a ruling from the Indian Supreme Court. That ruling could come soon.
_______________________________
Join Us: News for people demanding a better world
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Pharmaceutical giant Bayer has been dealt a blow with a precedent-setting ruling that allows the production of a low-cost version of its patented cancer drug Nexavar in India, vastly expanding access to the drug and challenging the global pharmaceutical monopolies that put potentially life-saving drugs out of reach for many.
On Monday, the Intellectual Property Appellate Board (IPAB) upheld a compulsory license given by India last year to Hyderabad-based Natco Pharma for its generic version of Nexavar, used in the treatment of kidney and liver cancer, dismissing a plea from Bayer to overturn that license.
As Reuters explains,
Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licenses on certain drugs that are deemed unaffordable to a large section of their populations.
Natco Pharma's version costs roughly 97% less than Bayer's Nexavar.
The ruling, the first in which the IPAB said the use of a compulsory license was legal, also stated that Natco would have to pay Bayer 7% in royalties for the drug.
In an interview with The Economic Times, Finance Director of Natco Pharma Bhaskar Narayana stated the importance of the landmark ruling.
"This only means that the IPAB has reaffirmed the crucial concept of making life-saving medicines available and affordable to the suffering masses. Therefore, it is big news not only for Natco Pharma, but also for the millions of cancer patients who cannot afford high value drugs," stated Narayana.
Health groups cheered the decision as well.
"The decision means that the way has been paved for compulsory licenses to be issued on other drugs, now patented in India and priced out of affordable reach, to be produced by generic companies and sold at a fraction of the price," BBC News quoted Leena Menghaney of the medical charity Medecins Sans Frontieres (MSF) as saying.
While representing a victory for people, the Connecticut Law Tribune points out how the ruling may leave big pharmaceutical firms shaking:
This is exactly what multinational pharmaceutical companies fear. While this is the first case of a compulsory license in India, drug makers are worried about their patents in India for other reasons. The country has already revoked some patents granted to Pfizer, Roche Holding AG, and Merck & Co., for example. And it rejected Swiss drug maker Novartis's patent application for the leukemia drug Glivec. Novartis appealed that ruling, and has been awaiting a ruling from the Indian Supreme Court. That ruling could come soon.
_______________________________
Pharmaceutical giant Bayer has been dealt a blow with a precedent-setting ruling that allows the production of a low-cost version of its patented cancer drug Nexavar in India, vastly expanding access to the drug and challenging the global pharmaceutical monopolies that put potentially life-saving drugs out of reach for many.
On Monday, the Intellectual Property Appellate Board (IPAB) upheld a compulsory license given by India last year to Hyderabad-based Natco Pharma for its generic version of Nexavar, used in the treatment of kidney and liver cancer, dismissing a plea from Bayer to overturn that license.
As Reuters explains,
Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licenses on certain drugs that are deemed unaffordable to a large section of their populations.
Natco Pharma's version costs roughly 97% less than Bayer's Nexavar.
The ruling, the first in which the IPAB said the use of a compulsory license was legal, also stated that Natco would have to pay Bayer 7% in royalties for the drug.
In an interview with The Economic Times, Finance Director of Natco Pharma Bhaskar Narayana stated the importance of the landmark ruling.
"This only means that the IPAB has reaffirmed the crucial concept of making life-saving medicines available and affordable to the suffering masses. Therefore, it is big news not only for Natco Pharma, but also for the millions of cancer patients who cannot afford high value drugs," stated Narayana.
Health groups cheered the decision as well.
"The decision means that the way has been paved for compulsory licenses to be issued on other drugs, now patented in India and priced out of affordable reach, to be produced by generic companies and sold at a fraction of the price," BBC News quoted Leena Menghaney of the medical charity Medecins Sans Frontieres (MSF) as saying.
While representing a victory for people, the Connecticut Law Tribune points out how the ruling may leave big pharmaceutical firms shaking:
This is exactly what multinational pharmaceutical companies fear. While this is the first case of a compulsory license in India, drug makers are worried about their patents in India for other reasons. The country has already revoked some patents granted to Pfizer, Roche Holding AG, and Merck & Co., for example. And it rejected Swiss drug maker Novartis's patent application for the leukemia drug Glivec. Novartis appealed that ruling, and has been awaiting a ruling from the Indian Supreme Court. That ruling could come soon.
_______________________________
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.